化合物 SRI-41315 T61306
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
5 mg | 1613509-49-1 | ¥913.00 | 询底价 |
100 mg | 1613509-49-1 | ¥7,890.00 | 询底价 |
2 mg | 1613509-49-1 | ¥554.00 | 询底价 |
10 mg | 1613509-49-1 | ¥1,710.00 | 询底价 |
Product Introduction
Bioactivity
英文名: SRI-41315
描述: SRI-41315, a chemical compound, effectively addresses premature termination codons (PTCs) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells. It induces a prolonged pause at stop codons, resulting in the restoration of cystic fibrosis transmembrane conductance regulator (CFTR) expression and function. This compound achieves PTC suppression by reducing the abundance of the termination factor eRF1. Additionally, SRI-41315 synergistically enhances CFTR activity by potentiating aminoglycoside-mediated readthrough [1].
体外活性: SRI-41315 exhibits target cell cytotoxicity (CC50) values >50 μM in both FRT and 16BE14o- cells [1]. SRI-41315 shows improved potency and efficacy in FRT cells that translated to 16HBE14o- cells [1]. SRI-41315 (5 μM, 20 h) depletes eRF1 levels through a proteasome-mediated degradation pathway [1]. Western Blot Analysis [1] Cell Line: CFTR-G542X 16HBEge G542X cells Concentration: 5 μM Incubation Time: 20 h Result: Depleted eRF1 levels through a proteasome-mediated degradation pathway. SRI-41315-mediated eRF1 degradation was prevented by the addition of (S)-MG132 but not the neddylation inhibitor MLN4924.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
化合物 SRI-41315 T61306信息由TargetMol中国为您提供,如您想了解更多关于化合物 SRI-41315 T61306报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途